Showing 1031-1040 of 1576 results for "".
- Moran Eye Center Lab Produces World’s First ‘Pathoconnectome’https://modernod.com/news/moran-eye-center-lab-produces-worlds-first-pathoconnectome/2478338/Scientists from the John A. Moran Eye Center at the University of Utah have achieved another first in the field of connectomics, which studies the synaptic connections between neurons. Moran’s Marclab for Connectomics was the first to complete a map of the circuitry of the retina, or conne
- Researchers Look To Behavior To Explore Why The Coronavirus May Hit Men Harderhttps://modernod.com/news/researchers-look-to-behavior-to-explore-why-the-coronavirus-may-hit-men-harder/2477641/Researchers suspect that the coronavirus is hitting men and women differently. Worldwide, men appear more likely to suffer more severely or die from COVID-19 than women. But experts don’t know why. At Johns Hopkins University, researchers have begun to
- Could a Hormone be Used to Treat Eye Disease?https://modernod.com/news/could-a-hormone-be-used-to-treat-eye-disease/2477314/John A. Moran Eye Center researchers continue to shed new light on the potential of the hormone erythropoietin (EPO) to treat eye disease. EPO increases red blood cell production, and is already used clinically to treat anemia. However, more recently EPO is being recognized for other properties,
- Second Sight Announces $2.4 Million, 4-Year Grant from NIH to Develop Spatial Localization and Mapping Technologyhttps://modernod.com/news/second-sight-announces-2-4-million-4-year-grant-from-nih-to-develop-spatial-localization-and-mapping-technology/2476926/Second Sight Medical Products announced receipt of a $2.4 million, 4-year grant from the National Institutes of Health (NIH) to develop spatial localization and mapping technology (SLAM). A joint collaboration with the Johns Hopkins University Applied Physics Laboratory (APL), the initiative is i
- Oyster Point Pharma Expands Executive Leadership Teamhttps://modernod.com/news/oyster-point-pharma-expands-executive-leadership-team/2476896/Oyster Point Pharma announced the appointment of Dan Lochner, MBA, as its Chief Financial Officer, and John Snisarenko, MBA, as Chief Commercial Officer. Mr. Lochner joins Oyster Point Pharma after spending nearly 15 years, most recently as a Managing Director, at Goldman Sachs asset mana
- Investigators Seek Optimized Ophthalmology Clinical Trial Outcomeshttps://modernod.com/news/investigators-seek-optimized-ophthalmology-clinical-trial-outcomes/2476338/Investigators from Brown University and Johns Hopkins University shared new considerations from 3 groups working to standardize Core Outcome Sets (COSs), to increase the utility of results from randomized clinical trials for 3 eye conditions: age-related macular degeneration (AMD), refractive err
- Pennsylvania Senate Approves Bill That Would Expand Optometrists’ Scope of Practicehttps://modernod.com/news/pennsylvania-senate-approves-bill-that-would-expand-optometrists-scope-of-practice/2479790/A Pennsylvania bill – Senate Bill (SB) 668, introduced by Sen. John Gordner – seeks to expand optometrists’ scope of practice beyond the limits of their training. The bill passed the full Senate by a vote of 32-17 on Sept. 25, 2018, and it now awaits consideration by the House Professional Licens
- Ciliatech Presents Preliminary 1-Year Study Results on Treating Open and Narrow Angle Glaucoma with CIDhttps://modernod.com/news/ciliatech-presents-preliminary-1-year-study-results-on-treating-open-and-narrow-angle-glaucoma-with-cid/2481814/Ciliatech announced it will present at the Ophthalmology Futures Symposium the preliminary results of a 1-year study of its clinical trial, SAFARI III, involving both open and narrow angle glaucoma patients. Preliminary outcomes show an excellent performance and safety profile, wit
- Novartis: Phase 3 Beovu Data Show Potential for Fluid Resolution in More DME Patients With Fewer Injections Versus Aflibercepthttps://modernod.com/news/novartis-phase-3-beovu-data-show-potential-for-fluid-resolution-in-more-dme-patients-with-fewer-injections-versus-aflibercept/2479150/Novartis announced positive 1-year results of the phase III KESTREL and KITE studies, evaluating the efficacy and safety of Beovu (brolucizumab-dbll) 6 mg in diabetic macular edema (DME). Both studies met their primary endpoints of noninferiority in change in best corrected visual acuity (
- ELT Sight’s ExTra Excimer Laser Trabeculostomy Procedure Receives New CPT Codeshttps://modernod.com/news/elt-sights-extra-excimer-laser-trabeculostomy-procedure-receives-new-cpt-codes/2477680/ELT Sight announced that the American Medical Association (AMA) approved two new Category III Current Procedural Terminology (CPT) codes to report ELT Sight’s ExTra Excimer Laser Trabeculostomy (ELT) procedure. The two new codes, to be used for reporting trabeculostomy ab interno by laser with or